Nicoderm C-Q Transdermal Product — Competitive Intelligence Brief

Nicoderm C-Q Transdermal Product (Nicoderm C-Q Transdermal Product) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nicotine replacement therapy (NRT). Area: Addiction Medicine / Smoking Cessation.

marketed Nicotine replacement therapy (NRT) Nicotinic acetylcholine receptors Addiction Medicine / Smoking Cessation Small molecule

Target snapshot

Nicoderm C-Q Transdermal Product (Nicoderm C-Q Transdermal Product) — University of Miami. Nicoderm CQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nicoderm C-Q Transdermal Product TARGET	Nicoderm C-Q Transdermal Product	University of Miami	marketed	Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Nicotine Patch and Nicotine Lozenge	Nicotine Patch and Nicotine Lozenge	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Transdermal nicotine patch	Transdermal nicotine patch	University of Pennsylvania	marketed	Nicotinic acetylcholine receptor agonist	Nicotinic acetylcholine receptors
Extended Duration Combination NRT	Extended Duration Combination NRT	University of Wisconsin, Madison	marketed	Nicotine replacement therapy (combination)	Nicotinic acetylcholine receptors
Galantamine-CR	Galantamine-CR	Massachusetts General Hospital	marketed	Cholinesterase inhibitor with nicotinic receptor allosteric modulator	Acetylcholinesterase; nicotinic acetylcholine receptors
Placebo/Galantamine (Reminyl®)	Placebo/Galantamine (Reminyl®)	Ludwig-Maximilians - University of Munich	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase; nicotinic acetylcholine receptors
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nicotine replacement therapy (NRT) class)

1. University of Wisconsin, Madison · 4 drugs in this class
2. Ottawa Heart Institute Research Corporation · 1 drug in this class
3. The Scripps Research Institute · 1 drug in this class
4. US Department of Veterans Affairs · 1 drug in this class
5. Chrono Therapeutics, Inc. · 1 drug in this class
6. University of Chicago · 1 drug in this class
7. University of Maryland, Baltimore · 1 drug in this class
8. University of Miami · 1 drug in this class
9. University of California, San Francisco · 1 drug in this class